Kazia Therapeutics (KZIA): EVT801 Data Published in Peer-Reviewed Journal
Kazia Therapeutics has published pre-clinical data for EVT801 in Cancer Research Communications, showcasing its potential as a selective VEGFR3 inhibitor, which could present a less toxic alternative to existing treatments like Votrient and Nexavar. The asset was in-licensed in 2021, and initial clinical trial data is expected in H1 2023. The company's valuation is now updated to $143.9 million (or $8.81 per basic ADR), reflecting around US$4 million raised so far in 2023.
- Publication of EVT801 pre-clinical data can enhance investor confidence.
- Selectively targeting VEGFR3 may result in better therapeutic outcomes.
- Valuation increased to $143.9 million, indicating positive market reception.
- Dependence on upcoming Phase I clinical trial data could introduce volatility.
- Potential dilution from additional shares issued under the ATM facility.
LONDON, UK / ACCESSWIRE / December 9, 2022 / Kazia Therapeutics has announced the publication of pre-clinical data for its second pipeline asset, EVT801 in the journal Cancer Research Communications. The research was conducted by licensing partner Evotec and was the key driver for Kazia in-licensing the asset in 2021. EVT801 is an inhibitor of vascular endothelial growth factor receptors (VEGFR), which play an important role in angiogenesis and lymphangiogenesis (processes that contribute to tumor growth and metastasis), making VEGFR a well-established therapeutic target. While VEGFR inhibitors have been on the market for over a decade, Kazia asserts that by selectively targeting VEGFR3, EVT801 offers a potent and less toxic therapeutic profile than other benchmark drugs, such as Novartis' Votrient (pazopanib) and Bayer's Nexavar (sorafenib). EVT801 is currently in a Phase I clinical trial with initial data expected in H1 CY23. Our valuation changes slightly to
We update our valuation for the latest issues under the ATM facility, which we estimate has contributed c US
Click here to view the full report or here to sign up to receive research as it is published.
All reports published by Edison are available to download free of charge from its website
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Soo Romanoff +44 (0)20 3077 5700 healthcare@edisongroup.com
Jyoti Prakash, CFA +44 (0)20 3077 5700 healthcare@edisongroup.com
Learn more atwww.edisongroup.com and connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison Group
View source version on accesswire.com:
https://www.accesswire.com/731093/Kazia-Therapeutics-KZIA-EVT801-Data-Published-in-Peer-Reviewed-Journal
FAQ
What is the significance of Kazia's EVT801 publication?
What is Kazia's current valuation?
When is the initial data for EVT801 expected?
How much funding has Kazia raised in H1 2023?
What risks are associated with Kazia's upcoming clinical trials?
